Jump to content

Welcome to Team-BRH.com :: A Gaming Community

Welcome to Team-BRH.com :: A Gaming Community, like most online communities you must register to post in our community. Don't worry, this is a simple and free process that requires minimal information for you to signup. Be apart of Team-BRH.com :: A Gaming Community by signing in or creating an account today!
  • Start new topics and reply to others
  • Subscribe to topics and forums to get automatic updates
  • Get your own profile and make new friends
  • Customize your experience here
  • Apply to join BRH!
Guest Message by DevFuse
 

Photo

Horse Medicine


  • Please log in to reply
No replies to this topic

#1
OFFLINE   CanMan

CanMan
  • Admin
  • 1570 posts
  • Location:
    Toronto

  • Preferred Game:
    TF2

  • Favorite Drink(s):
    Guinness

User's Awards

        

https://journals.lww...tment_of.7.aspx

 

Abstract
Background: 

Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

Areas of uncertainty: 

We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

Data sources: 

We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.

Therapeutic Advances: 

Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty.

Conclusions: 

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

 


Posted Image




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users